Skip to content
CancerIndex

Publication

Neoadjuvant triplet chemotherapy enables radiotherapy avoidance in human papillomavirus-associated oropharyngeal cancer: a multicentre Phase II trial.

Tomoya Yokota, Toyonori Tsuzuki, Tetsuro Onitsuka, Akira Iizuka, Yohei Ouchi, Terushige Mori, Kiyoaki Tsukahara, Kenji Hanyu, Takashi Mukaigawa, Torahiko Nakashima, Hideoki Uryu, Go Omura, Hiromu Nakamura, Hirokazu Uemura, Daisuke Nishikawa, Satoshi Kano, Yasuto Akiyama, Tsuyoshi Onoe, Shunsuke Oyamada, Takuhiro Yamaguchi

British journal of cancerSep 5, 2026PMID 42701122doi:10.1038/s41416-026-03610-y Journal ArticlepubmedProvenance
Source
PubMed
Retrieved
Sep 30, 2026
Layer
normalized (units and labels harmonized; values unchanged)
Run
ING-PUBMED-20260930-000001
Published

Abstract

Abstract (excerpt)

Only the opening of the abstract is shown; abstract text may carry publisher copyright.

BACKGROUND: This prospective Phase 2 trial assessed a novel de-escalation strategy for upfront neoadjuvant chemotherapy with docetaxel, cisplatin, and 5-fluorouracil (NAC-TPF) to avoid postoperative radiotherapy (PORT) and chemoradiotherapy (POCRT) for human papillomavirus (HPV)-associated…

Read on PubMed

Linked entities

Linked entities (1)

How each link was made (MeSH, dictionary, registry reference, curation…) and whether it has been validated. Candidate links are not counted in entity statistics.

Candidate 1

Curated evidence

Evidence citing this paper (0)

Data not yet available

No curated evidence item cites this publication.